Budget victory in US, but FDA, NIH could still be appropriations losers
This article was originally published in Clinica
The US Senate voted 64-36 on 18 December to send a two-year budget agreement to President Barack Obama for his signature, ensuring the US federal government won't face a shutdown on 15 January when the current spending authority is due to end.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.